Because, Ewing's sarcoma initially responds to DNA damaging agents, for which cell killing depends on SLFN11 [22, 24, 44], it will be important to determine the SLFN11 status of tumors in patients at relapse. This evidence concerns the gene SLFN11 and Ewing sarcoma.